<?xml version='1.0' encoding='UTF-8'?>
<Organism_Record>
  <Organism_ID>ASD02320000_1</Organism_ID>
  <Organism>Human</Organism>
  <Organism_Latin>Homo sapiens</Organism_Latin>
  <UniProt_ID>P00747</UniProt_ID>
  <Seq_Length>810</Seq_Length>
  <Molecule_Weight>90569</Molecule_Weight>
  <KEGG_ID>hsa:5340</KEGG_ID>
  <Orthology_ID>K01315</Orthology_ID>
  <EBI_ID>EBI-999394</EBI_ID>
  <Function_Summary>Plasmin dissolves the fibrin of blood clots and acts as a proteolytic factor in a variety of other processes including embryonic development, tissue remodeling, tumor invasion, and inflammation. In ovulation, weakens the walls of the Graafian follicle. It activates the urokinase-type plasminogen activator, collagenases and several complement zymogens, such as C1 and C5. Cleavage of fibronectin and laminin leads to cell detachment and apoptosis. Also cleaves fibrin, thrombospondin and von Willebrand factor. Its role in tissue remodeling and tumor invasion may be modulated by CSPG4. Binds to cells.Angiostatin is an angiogenesis inhibitor that blocks neovascularization and growth of experimental primary and metastatic tumors in vivo.</Function_Summary>
  <Catalytic_Mechanism>Preferential cleavage: Lys-|-Xaa </Catalytic_Mechanism>
  <Pfam_ID>PF00051:Kringle@@PF00024:PAN_1@@PF00089:Trypsin</Pfam_ID>
  <Allosteric_Activator_Count>0</Allosteric_Activator_Count>
  <Allosteric_Inhibitor_Count>59</Allosteric_Inhibitor_Count>
  <Allosteric_Regulator_Count>0</Allosteric_Regulator_Count>
  <Alias_List>
      <Alias>Plasmin</Alias>
  </Alias_List>
  <Function_List>
    <Funtion>
      <Detail>Catalysis of the hydrolysis of internal, alpha-peptide bonds in a polypeptide chain by a catalytic mechanism that involves a catalytic triad consisting of a serine nucleophile that is activated by a proton relay involving an acidic residue (e.g. aspartate or glutamate) and a basic residue (usually histidine).</Detail>
      <Keyword>Serine-type endopeptidase activity</Keyword>
      <Ontology_ID>GO:0004252</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>OBSOLETE. Catalysis of the preferential cleavage of Lys-Xaa &gt; Arg-Xaa; higher selectivity than trypsin. Converts fibrin into soluble products.</Detail>
      <Keyword>Plasmin activity</Keyword>
      <Ontology_ID>GO:0004283</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with a specific domain of a protein.</Detail>
      <Keyword>Protein domain specific binding</Keyword>
      <Ontology_ID>GO:0019904</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with an apolipoprotein, the protein component of a lipoprotein complex.</Detail>
      <Keyword>Apolipoprotein binding</Keyword>
      <Ontology_ID>GO:0034185</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with any component on the surface of a cell.</Detail>
      <Keyword>Cell surface binding</Keyword>
      <Ontology_ID>GO:0043498</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Catalysis of the hydrolysis of a peptide bond. A peptide bond is a covalent bond formed when the carbon atom from the carboxyl group of one amino acid shares electrons with the nitrogen atom from the amino group of a second amino acid.</Detail>
      <Keyword>Peptidase activity</Keyword>
      <Ontology_ID>GO:0008233</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Catalysis of the hydrolysis of various bonds, e.g. C-O, C-N, C-C, phosphoric anhydride bonds, etc. Hydrolase is the systematic name for any enzyme of EC class 3.</Detail>
      <Keyword>Hydrolase activity</Keyword>
      <Ontology_ID>GO:0016787</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Catalysis of the hydrolysis of peptide bonds in a polypeptide chain by a catalytic mechanism that involves a catalytic triad consisting of a serine nucleophile that is activated by a proton relay involving an acidic residue (e.g. aspartate or glutamate) and a basic residue (usually histidine).</Detail>
      <Keyword>Serine-type peptidase activity</Keyword>
      <Ontology_ID>GO:0008236</Ontology_ID>
    </Funtion>
  </Function_List>
  <Mutation_List>
    <Muntion>
      <Position>133</Position>
      <Original>His</Original>
      <Variation>Gln</Variation>
    </Muntion>
    <Muntion>
      <Position>374</Position>
      <Original>Val</Original>
      <Variation>Phe</Variation>
    </Muntion>
    <Muntion>
      <Position>46</Position>
      <Original>Ile</Original>
      <Variation>Arg</Variation>
    </Muntion>
    <Muntion>
      <Position>408</Position>
      <Original>Arg</Original>
      <Variation>Trp</Variation>
    </Muntion>
    <Muntion>
      <Position>676</Position>
      <Original>Val</Original>
      <Variation>Asp</Variation>
    </Muntion>
    <Muntion>
      <Position>235</Position>
      <Original>Arg</Original>
      <Variation>His</Variation>
    </Muntion>
    <Muntion>
      <Position>523</Position>
      <Original>Arg</Original>
      <Variation>Trp</Variation>
    </Muntion>
    <Muntion>
      <Position>38</Position>
      <Original>Lys</Original>
      <Variation>Glu</Variation>
    </Muntion>
    <Muntion>
      <Position>453</Position>
      <Original>Lys</Original>
      <Variation>Ile</Variation>
    </Muntion>
    <Muntion>
      <Position>134</Position>
      <Original>Arg</Original>
      <Variation>Lys</Variation>
    </Muntion>
    <Muntion>
      <Position>751</Position>
      <Original>Gly</Original>
      <Variation>Arg</Variation>
    </Muntion>
    <Muntion>
      <Position>532</Position>
      <Original>Arg</Original>
      <Variation>His</Variation>
    </Muntion>
    <Muntion>
      <Position>591</Position>
      <Original>Ser</Original>
      <Variation>Pro</Variation>
    </Muntion>
    <Muntion>
      <Position>472</Position>
      <Original>Asp</Original>
      <Variation>Asn</Variation>
    </Muntion>
    <Muntion>
      <Position>57</Position>
      <Original>Glu</Original>
      <Variation>Lys</Variation>
    </Muntion>
    <Muntion>
      <Position>494</Position>
      <Original>Ala</Original>
      <Variation>Val</Variation>
    </Muntion>
    <Muntion>
      <Position>147</Position>
      <Original>Leu</Original>
      <Variation>Pro</Variation>
    </Muntion>
    <Muntion>
      <Position>261</Position>
      <Original>Arg</Original>
      <Variation>His</Variation>
    </Muntion>
    <Muntion>
      <Position>620</Position>
      <Original>Ala</Original>
      <Variation>Thr</Variation>
    </Muntion>
  </Mutation_List>
  <BioProcess_List>
    <BioProcess>
      <Detail>A series of progressive, overlapping events triggered by exposure of the platelets to subendothelial tissue. These events include shape change, adhesiveness, aggregation, and release reactions. When carried through to completion, these events lead to the formation of a stable hemostatic plug.</Detail>
      <Keyword>Platelet activation</Keyword>
      <Ontology_ID>GO:0030168</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The stopping of bleeding (loss of body fluid) or the arrest of the circulation to an organ or part.</Detail>
      <Keyword>Hemostasis</Keyword>
      <Ontology_ID>GO:0007599</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates, maintains or increases the frequency, rate or extent of fibrinolysis, an ongoing process that solubilizes fibrin, resulting in the removal of small blood clots.</Detail>
      <Keyword>Positive regulation of fibrinolysis</Keyword>
      <Ontology_ID>GO:0051919</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>A process that results in the breakdown of the extracellular matrix.</Detail>
      <Keyword>Extracellular matrix disassembly</Keyword>
      <Ontology_ID>GO:0022617</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>An ongoing process that solubilizes fibrin, chiefly by the proteolytic action of plasmin, resulting in the removal of small blood clots.</Detail>
      <Keyword>Fibrinolysis</Keyword>
      <Ontology_ID>GO:0042730</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that stops, prevents or reduces the rate or extent of cell proliferation.</Detail>
      <Keyword>Negative regulation of cell proliferation</Keyword>
      <Ontology_ID>GO:0008285</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that stops, prevents, or reduces the frequency, rate or extent of cell-cell adhesion mediated by cadherin.</Detail>
      <Keyword>Negative regulation of cell-cell adhesion mediated by cadherin</Keyword>
      <Ontology_ID>GO:2000048</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that decreases the frequency, rate or extent of cell-substrate adhesion. Cell-substrate adhesion is the attachment of a cell to the underlying substrate via adhesion molecules.</Detail>
      <Keyword>Negative regulation of cell-substrate adhesion</Keyword>
      <Ontology_ID>GO:0010812</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that stops, prevents, or reduces the frequency, rate or extent of fibrinolysis, an ongoing process that solubilizes fibrin, resulting in the removal of small blood clots.</Detail>
      <Keyword>Negative regulation of fibrinolysis</Keyword>
      <Ontology_ID>GO:0051918</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The reorganization or renovation of existing tissues. This process can either change the characteristics of a tissue such as in blood vessel remodeling, or result in the dynamic equilibrium of a tissue such as in bone remodeling.</Detail>
      <Keyword>Tissue remodeling</Keyword>
      <Ontology_ID>GO:0048771</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The regulated exocytosis of secretory granules containing preformed mediators such as histamine and serotonin by a platelet.</Detail>
      <Keyword>Platelet degranulation</Keyword>
      <Ontology_ID>GO:0002576</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The sequential process in which the multiple coagulation factors of the blood interact, ultimately resulting in the formation of an insoluble fibrin clot; it may be divided into three stages: stage 1, the formation of intrinsic and extrinsic prothrombin converting principle; stage 2, the formation of thrombin; stage 3, the formation of stable fibrin polymers.</Detail>
      <Keyword>Blood coagulation</Keyword>
      <Ontology_ID>GO:0007596</Ontology_ID>
    </BioProcess>
  </BioProcess_List>
  <PTM_List>
    <PTM>
      <Position>597</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
  </PTM_List>
  <Molecule_Seq>
    <Protein_Seq>MEHKEVVLLLLLFLKSGQGEPLDDYVNTQGASLFSVTKKQLGAGSIEECAAKCEEDEEFTCRAFQYHSKEQQCVIMAENRKSSIIIRMRDVVLFEKKVYLSECKTGNGKNYRGTMSKTKNGITCQKWSSTSPHRPRFSPATHPSEGLEENYCRNPDNDPQGPWCYTTDPEKRYDYCDILECEEECMHCSGENYDGKISKTMSGLECQAWDSQSPHAHGYIPSKFPNKNLKKNYCRNPDRELRPWCFTTDPNKRWELCDIPRCTTPPPSSGPTYQCLKGTGENYRGNVAVTVSGHTCQHWSAQTPHTHNRTPENFPCKNLDENYCRNPDGKRAPWCHTTNSQVRWEYCKIPSCDSSPVSTEQLAPTAPPELTPVVQDCYHGDGQSYRGTSSTTTTGKKCQSWSSMTPHRHQKTPENYPNAGLTMNYCRNPDADKGPWCFTTDPSVRWEYCNLKKCSGTEASVVAPPPVVLLPDVETPSEEDCMFGNGKGYRGKRATTVTGTPCQDWAAQEPHRHSIFTPETNPRAGLEKNYCRNPDGDVGGPWCYTTNPRKLYDYCDVPQCAAPSFDCGKPQVEPKKCPGRVVGGCVAHPHSWPWQVSLRTRFGMHFCGGTLISPEWVLTAAHCLEKSPRPSSYKVILGAHQEVNLEPHVQEIEVSRLFLEPTRKDIALLKLSSPAVITDKVIPACLPSPNYVVADRTECFITGWGETQGTFGAGLLKEAQLPVIENKVCNRYEFLNGRVQSTELCAGHLAGGTDSCQGDSGGPLVCFEKDKYILQGVTSWGLGCARPNKPGVYVRVSRFVTWIEGVMRNN</Protein_Seq>
    <DNA_Seq>AACAACATCCTGGGATTGGGACCCACTTTCTGGGCACTGCTGGCCAGTCCCAAAATGGAACATAAGGAAGTGGTTCTTCTACTTCTTTTATTTCTGAAATCAGGTCAAGGAGAGCCTCTGGATGACTATGTGAATACCCAGGGGGCTTCACTGTTCAGTGTCACTAAGAAGCAGCTGGGAGCAGGAAGTATAGAAGAATGTGCAGCAAAATGTGAGGAGGACGAAGAATTCACCTGCAGGGCATTCCAATATCACAGTAAAGAGCAACAATGTGTGATAATGGCTGAAAACAGGAAGTCCTCCATAATCATTAGGATGAGAGATGTAGTTTTATTTGAAAAGAAAGTGTATCTCTCAGAGTGCAAGACTGGGAATGGAAAGAACTACAGAGGGACGATGTCCAAAACAAAAAATGGCATCACCTGTCAAAAATGGAGTTCCACTTCTCCCCACAGACCTAGATTCTCACCTGCTACACACCCCTCAGAGGGACTGGAGGAGAACTACTGCAGGAATCCAGACAACGATCCGCAGGGGCCCTGGTGCTATACTACTGATCCAGAAAAGAGATATGACTACTGCGACATTCTTGAGTGTGAAGAGGAATGTATGCATTGCAGTGGAGAAAACTATGACGGCAAAATTTCCAAGACCATGTCTGGACTGGAATGCCAGGCCTGGGACTCTCAGAGCCCACACGCTCATGGATACATTCCTTCCAAATTTCCAAACAAGAACCTGAAGAAGAATTACTGTCGTAACCCCGATAGGGAGCTGCGGCCTTGGTGTTTCACCACCGACCCCAACAAGCGCTGGGAACTTTGCGACATCCCCCGCTGCACAACACCTCCACCATCTTCTGGTCCCACCTACCAGTGTCTGAAGGGAACAGGTGAAAACTATCGCGGGAATGTGGCTGTTACCGTTTCCGGGCACACCTGTCAGCACTGGAGTGCACAGACCCCTCACACACATAACAGGACACCAGAAAACTTCCCCTGCAAAAATTTGGATGAAAACTACTGCCGCAATCCTGACGGAAAAAGGGCCCCATGGTGCCATACAACCAACAGCCAAGTGCGGTGGGAGTACTGTAAGATACCGTCCTGTGACTCCTCCCCAGTATCCACGGAACAATTGGCTCCCACAGCACCACCTGAGCTAACCCCTGTGGTCCAGGACTGCTACCATGGTGATGGACAGAGCTACCGAGGCACATCCTCCACCACCACCACAGGAAAGAAGTGTCAGTCTTGGTCATCTATGACACCACACCGGCACCAGAAGACCCCAGAAAACTACCCAAATGCTGGCCTGACAATGAACTACTGCAGGAATCCAGATGCCGATAAAGGCCCCTGGTGTTTTACCACAGACCCCAGCGTCAGGTGGGAGTACTGCAACCTGAAAAAATGCTCAGGAACAGAAGCGAGTGTTGTAGCACCTCCGCCTGTTGTCCTGCTTCCAGATGTAGAGACTCCTTCCGAAGAAGACTGTATGTTTGGGAATGGGAAAGGATACCGAGGCAAGAGGGCGACCACTGTTACTGGGACGCCATGCCAGGACTGGGCTGCCCAGGAGCCCCATAGACACAGCATTTTCACTCCAGAGACAAATCCACGGGCGGGTCTGGAAAAAAATTACTGCCGTAACCCTGATGGTGATGTAGGTGGTCCCTGGTGCTACACGACAAATCCAAGAAAACTTTACGACTACTGTGATGTCCCTCAGTGTGCGGCCCCTTCATTTGATTGTGGGAAGCCTCAAGTGGAGCCGAAGAAATGTCCTGGAAGGGTTGTGGGGGGGTGTGTGGCCCACCCACATTCCTGGCCCTGGCAAGTCAGTCTTAGAACAAGGTTTGGAATGCACTTCTGTGGAGGCACCTTGATATCCCCAGAGTGGGTGTTGACTGCTGCCCACTGCTTGGAGAAGTCCCCAAGGCCTTCATCCTACAAGGTCATCCTGGGTGCACACCAAGAAGTGAATCTCGAACCGCATGTTCAGGAAATAGAAGTGTCTAGGCTGTTCTTGGAGCCCACACGAAAAGATATTGCCTTGCTAAAGCTAAGCAGTCCTGCCGTCATCACTGACAAAGTAATCCCAGCTTGTCTGCCATCCCCAAATTATGTGGTCGCTGACCGGACCGAATGTTTCATCACTGGCTGGGGAGAAACCCAAGGTACTTTTGGAGCTGGCCTTCTCAAGGAAGCCCAGCTCCCTGTGATTGAGAATAAAGTGTGCAATCGCTATGAGTTTCTGAATGGAAGAGTCCAATCCACCGAACTCTGTGCTGGGCATTTGGCCGGAGGCACTGACAGTTGCCAGGGTGACAGTGGAGGTCCTCTGGTTTGCTTCGAGAAGGACAAATACATTTTACAAGGAGTCACTTCTTGGGGTCTTGGCTGTGCACGCCCCAATAAGCCTGGTGTCTATGTTCGTGTTTCAAGGTTTGTTACTTGGATTGAGGGAGTGATGAGAAATAATTAATTGGACGGGAGACAGAGTGACGCACTGACTCACCTAGAGGCTGGGACGTGGGTAGGGATTTAGCATGCTGGAAATAACTGGCAGTAATCAAACGAAGACACTGTCCCCAGCTACCAGCTACGCCAAACCTCGGCATTTTTTGTGTTATTTTCTGACTGCTGGATTCTGTAGTAAGGTGACATAGCTATGACATTTGTTAAAAATAAACTCTGTACTTAACTTTGATTTGAGTAAATTTTGGTTTT</DNA_Seq>
  </Molecule_Seq>
  <Tissuelocal_List>
    <TissueLocal>
      <TissueLocal>Extracellular fluids</TissueLocal>
    </TissueLocal>
    <TissueLocal>
      <TissueLocal>Liver</TissueLocal>
    </TissueLocal>
    <TissueLocal>
      <TissueLocal>Plasma</TissueLocal>
    </TissueLocal>
  </Tissuelocal_List>
  <CellLocal_List>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Secreted</CellLocal>
    </AsdMacromoleculeCelllocal>
  </CellLocal_List>
  <Gene>
    <Gene_Name>PLG</Gene_Name>
    <Gene_ID>5340</Gene_ID>
    <Genbank_ACCN>NM_000301</Genbank_ACCN>
    <Protein_ACCN>NP_000292</Protein_ACCN>
    <HGNC_ID>9071</HGNC_ID>
    <Gene_URL>http://www.ncbi.nlm.nih.gov/gene/5340</Gene_URL>
    <UCSC_ID>uc003qtm.4</UCSC_ID>
    <EMBL_ID>ENSG00000122194</EMBL_ID>
  </Gene>
  <PPI_List>
    <PPI>
      <Uniprot_ID>P00747</Uniprot_ID>
      <Gene_Name>PLG</Gene_Name>
      <EBI_ID>EBI-984286</EBI_ID>
      <PPI_EBI_URL>EBI-999394,EBI-984286</PPI_EBI_URL>
      <Experiment_Number>2</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>P00779</Uniprot_ID>
      <Gene_Name>skc</Gene_Name>
      <EBI_ID>EBI-1035089</EBI_ID>
      <PPI_EBI_URL>EBI-999394,EBI-1035089</PPI_EBI_URL>
      <Experiment_Number>2</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>P00747</Uniprot_ID>
      <Gene_Name>PLG</Gene_Name>
      <EBI_ID>EBI-984118</EBI_ID>
      <PPI_EBI_URL>EBI-999394,EBI-984118</PPI_EBI_URL>
      <Experiment_Number>2</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>P00747</Uniprot_ID>
      <Gene_Name>PLG</Gene_Name>
      <EBI_ID>EBI-984197</EBI_ID>
      <PPI_EBI_URL>EBI-999394,EBI-984197</PPI_EBI_URL>
      <Experiment_Number>2</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>P00747</Uniprot_ID>
      <Gene_Name>PLG</Gene_Name>
      <EBI_ID>EBI-984250</EBI_ID>
      <PPI_EBI_URL>EBI-999394,EBI-984250</PPI_EBI_URL>
      <Experiment_Number>2</Experiment_Number>
    </PPI>
  </PPI_List>
  <Disease_List>
    <Disease>
      <Disease_Name>Malaria</Disease_Name>
      <Disease_Detail>Malaria</Disease_Detail>
      <Disease_DB>MLR004</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/malaria?search=PLG#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Hemangioendothelioma</Disease_Name>
      <Disease_Detail>Hemangioendothelioma</Disease_Detail>
      <Disease_DB>HMN016</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/hemangioendothelioma?search=PLG#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Congenital Plasminogen Deficiency</Disease_Name>
      <Disease_Detail>Congenital Plasminogen Deficiency</Disease_Detail>
      <Disease_DB>CNG171</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/congenital_plasminogen_deficiency?search=PLG#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Acute Poststreptococcal Glomerulonephritis</Disease_Name>
      <Disease_Detail>Acute Poststreptococcal Glomerulonephritis</Disease_Detail>
      <Disease_DB>ACT040</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/acute_poststreptococcal_glomerulonephritis?search=PLG#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Invasive Aspergillosis</Disease_Name>
      <Disease_Detail>Invasive Aspergillosis</Disease_Detail>
      <Disease_DB>INV001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/invasive_aspergillosis?search=PLG#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Chronic Myocardial Ischemia</Disease_Name>
      <Disease_Detail>Chronic Myocardial Ischemia</Disease_Detail>
      <Disease_DB>CHR413</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/chronic_myocardial_ischemia?search=PLG#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Dysplasminogenemia</Disease_Name>
      <Disease_Detail>Dysplasminogenemia</Disease_Detail>
      <Disease_DB>DYS157</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/dysplasminogenemia?search=PLG#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Thrombophilia</Disease_Name>
      <Disease_Detail>Thrombophilia</Disease_Detail>
      <Disease_DB>THR015</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/thrombophilia?search=PLG#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Conjunctivitis</Disease_Name>
      <Disease_Detail>Conjunctivitis</Disease_Detail>
      <Disease_DB>CNJ013</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/conjunctivitis?search=PLG#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Intracranial Thrombosis</Disease_Name>
      <Disease_Detail>Intracranial Thrombosis</Disease_Detail>
      <Disease_DB>INT078</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/intracranial_thrombosis?search=PLG#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Artery Disease</Disease_Name>
      <Disease_Detail>Artery Disease</Disease_Detail>
      <Disease_DB>ART111</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/artery_disease?search=PLG#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Corneal Neovascularization</Disease_Name>
      <Disease_Detail>Corneal Neovascularization</Disease_Detail>
      <Disease_DB>CRN027</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/corneal_neovascularization?search=PLG#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Pyogenic Granuloma</Disease_Name>
      <Disease_Detail>Pyogenic Granuloma</Disease_Detail>
      <Disease_DB>PYG006</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/pyogenic_granuloma?search=PLG#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Intermediate Coronary Syndrome</Disease_Name>
      <Disease_Detail>Intermediate Coronary Syndrome</Disease_Detail>
      <Disease_DB>INT007</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/intermediate_coronary_syndrome?search=PLG#related_genes</Disease_URL>
    </Disease>
  </Disease_List>
  <PDB_List>
    <PDB>
      <PDB_Title>Solution structure of the complex of VEK-30 and plasminogen kringle 2</PDB_Title>
      <PDB_ID>2KJ4</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.rcsb.org/pdb/explore/explore.do?structureId=2KJ4</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Solution structure of the complex of VEK-30 and plasminogen kringle 2.</PubMed_Title>
      <Author>Wang M, et al.</Author>
      <Journal>(2010) J.Struct.Biol. 169: 349-359</Journal>
      <PubMed_ID>19800007</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>STRUCTURE AND LIGAND DETERMINANTS OF THE RECOMBINANT KRINGLE 5 DOMAIN OF HUMAN PLASMINOGEN</PDB_Title>
      <PDB_ID>5HPG</PDB_ID>
      <Resolution>1.66</Resolution>
      <PDB_URL>http://www.rcsb.org/pdb/explore.do?structureId=5hpg</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structure and ligand binding determinants of the recombinant kringle 5 domain of human plasminogen.</PubMed_Title>
      <Author>Chang Y, et al.</Author>
      <Journal>(1998) Biochemistry 37: 3258-3271</Journal>
      <PubMed_ID>9521645</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>KRINGLE 2 DOMAIN OF HUMAN PLASMINOGEN: NMR SOLUTION STRUCTURE OF TRANS-4-AMINOMETHYLCYCLOHEXANE-1-CARBOXYLIC ACID (AMCHA) COMPLEX</PDB_Title>
      <PDB_ID>1B2I</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.rcsb.org/pdb/explore.do?structureId=1b2i</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Solution structure and dynamics of the plasminogen kringle 2-AMCHA complex: 3(1)-helix in homologous domains.</PubMed_Title>
      <Author>Marti DN, et al.</Author>
      <Journal>(1999) Biochemistry 38: 15741-15755</Journal>
      <PubMed_ID>10625440</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>SOLUTION NMR STRUCTURE OF THE HUMAN PLASMINOGEN KRINGLE 1 DOMAIN COMPLEXED WITH 6-AMINOHEXANOIC ACID AT PH 5.3, 310K, DERIVED FROM RANDOMLY GENERATED STRUCTURES USING SIMULATED ANNEALING, 12 STRUCTURES</PDB_Title>
      <PDB_ID>1HPJ</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.rcsb.org/pdb/explore.do?structureId=1hpj</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Solution structure of the epsilon-aminohexanoic acid complex of human plasminogen kringle 1.</PubMed_Title>
      <Author>Rejante MR, et al.</Author>
      <Journal>(1994) Eur.J.Biochem. 221: 939-949</Journal>
      <PubMed_ID>8181476</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>THE REFINED STRUCTURE OF THE EPSILON-AMINOCAPROIC ACID COMPLEX OF HUMAN PLASMINOGEN KRINGLE</PDB_Title>
      <PDB_ID>2PK4</PDB_ID>
      <Resolution>2.25</Resolution>
      <PDB_URL>http://www.rcsb.org/pdb/explore.do?structureId=2pk4</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>6-AMINOHEXANOIC ACID</Ligand_Name>
      <PubMed_Title>The refined structure of the epsilon-aminocaproic acid complex of human plasminogen kringle 4.</PubMed_Title>
      <Author>Wu TP, et al.</Author>
      <Journal>(1991) Biochemistry 30: 10589-10594</Journal>
      <PubMed_ID>1657149</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>THE STRUCTURE OF THE NON-COVALENT COMPLEX OF RECOMBINANT KRINGLE 1 DOMAIN OF HUMAN PLASMINOGEN WITH EACA (EPSILON-AMINOCAPROIC ACID)</PDB_Title>
      <PDB_ID>1CEA</PDB_ID>
      <Resolution>2.06</Resolution>
      <PDB_URL>http://www.rcsb.org/pdb/explore.do?structureId=1cea</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>6-AMINOHEXANOIC ACID</Ligand_Name>
      <PubMed_Title>Crystal structures of the recombinant kringle 1 domain of human plasminogen in complexes with the ligands epsilon-aminocaproic acid and trans-4-(aminomethyl)cyclohexane-1-carboxylic Acid.</PubMed_Title>
      <Author>Mathews II, et al.</Author>
      <Journal>(1996) Biochemistry 35: 2567-2576</Journal>
      <PubMed_ID>8611560</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTAL STRUCTURE OF HUMAN PLASMINOGEN CATALYTIC DOMAIN</PDB_Title>
      <PDB_ID>1DDJ</PDB_ID>
      <Resolution>2.0</Resolution>
      <PDB_URL>http://www.rcsb.org/pdb/explore.do?structureId=1ddj</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Human plasminogen catalytic domain undergoes an unusual conformational change upon activation.</PubMed_Title>
      <Author>Wang X, et al.</Author>
      <Journal>(2000) J.Mol.Biol. 295: 903-914</Journal>
      <PubMed_ID>10656799</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>SOLUTION NMR STRUCTURE OF THE HUMAN PLASMINOGEN KRINGLE 1 DOMAIN COMPLEXED WITH 6-AMINOHEXANOIC ACID AT PH 5.3, 310K, DERIVED FROM RANDOMLY GENERATED STRUCTURES USING SIMULATED ANNEALING, MINIMIZED AVERAGE STRUCTURE</PDB_Title>
      <PDB_ID>1HPK</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.rcsb.org/pdb/explore.do?structureId=1HPK</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>6-AMINOHEXANOIC ACID</Ligand_Name>
      <PubMed_Title>Solution structure of the epsilon-aminohexanoic acid complex of human plasminogen kringle 1.</PubMed_Title>
      <Author>Rejante MR, et al.</Author>
      <Journal>(1994) Eur.J.Biochem. 221: 939-949</Journal>
      <PubMed_ID>8181476</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>THE STRUCTURE OF THE NON-COVALENT COMPLEX OF RECOMBINANT KRINGLE 1 DOMAIN OF HUMAN PLASMINOGEN WITH AMCHA (TRANS-4-AMINOMETHYLCYCLOHEXANE-1-CARBOXYLIC ACID)</PDB_Title>
      <PDB_ID>1CEB</PDB_ID>
      <Resolution>2.07</Resolution>
      <PDB_URL>http://www.rcsb.org/pdb/explore.do?structureId=1CEB</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>TRANS-4-AMINOMETHYLCYCLOHEXANE-1-CARBOXYLIC ACID</Ligand_Name>
      <PubMed_Title>Crystal structures of the recombinant kringle 1 domain of human plasminogen in complexes with the ligands epsilon-aminocaproic acid and trans-4-(aminomethyl)cyclohexane-1-carboxylic Acid.</PubMed_Title>
      <Author>Mathews II, et al.</Author>
      <Journal>(1996) Biochemistry 35: 2567-2576</Journal>
      <PubMed_ID>8611560</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>COMPLEX OF THE CATALYTIC DOMAIN OF HUMAN PLASMIN AND STREPTOKINASE</PDB_Title>
      <PDB_ID>1BML</PDB_ID>
      <Resolution>2.9</Resolution>
      <PDB_URL>http://www.rcsb.org/pdb/explore.do?structureId=1bml</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystal structure of the catalytic domain of human plasmin complexed with streptokinase.</PubMed_Title>
      <Author>Wang X, et al.</Author>
      <Journal>(1998) Science 281: 1662-1665</Journal>
      <PubMed_ID>9733510</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>STRUCTURE AND BINDING DETERMINANTS OF THE RECOMBINANT KRINGLE-2 DOMAIN OF HUMAN PLASMINOGEN TO AN INTERNAL PEPTIDE FROM A GROUP A STREPTOCOCCAL SURFACE PROTEIN</PDB_Title>
      <PDB_ID>1I5K</PDB_ID>
      <Resolution>2.7</Resolution>
      <PDB_URL>http://www.rcsb.org/pdb/explore.do?structureId=1i5k</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structure and binding determinants of the recombinant kringle-2 domain of human plasminogen to an internal peptide from a group A Streptococcal surface protein.</PubMed_Title>
      <Author>Rios-Steiner JL, et al.</Author>
      <Journal>(2001) J.Mol.Biol. 308: 705-719</Journal>
      <PubMed_ID>11350170</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTAL AND MOLECULAR STRUCTURE OF HUMAN PLASMINOGEN KRINGLE 4 REFINED AT 1.9-ANGSTROMS RESOLUTION</PDB_Title>
      <PDB_ID>1PK4</PDB_ID>
      <Resolution>1.9</Resolution>
      <PDB_URL>http://www.rcsb.org/pdb/explore.do?structureId=1pk4</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystal and molecular structure of human plasminogen kringle 4 refined at 1.9-A resolution.</PubMed_Title>
      <Author>Mulichak AM, et al.</Author>
      <Journal>(1991) Biochemistry 30: 10576-10588</Journal>
      <PubMed_ID>1657148</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Solution structure and functional characterization of human plasminogen kringle 5</PDB_Title>
      <PDB_ID>2KNF</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.rcsb.org/pdb/explore/explore.do?structureId=2KNF</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Solution structure and functional characterization of human plasminogen kringle 5.</PubMed_Title>
      <Author>Battistel MD, et al.</Author>
      <Journal>(2009) Biochemistry 48: 10208-10219</Journal>
      <PubMed_ID>19821587</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Human PLASMINOGEN CATALYTIC DOMAIN, K698M MUTANT</PDB_Title>
      <PDB_ID>1RJX</PDB_ID>
      <Resolution>2.3</Resolution>
      <PDB_URL>http://www.rcsb.org/pdb/explore.do?structureId=1rjx</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Characterization of Lys-698-to-Met substitution in human plasminogen catalytic domain.</PubMed_Title>
      <Author>Terzyan S, et al.</Author>
      <Journal>(2004) Proteins 56: 277-284</Journal>
      <PubMed_ID>15211511</PubMed_ID>
    </PDB>
  </PDB_List>
  <Network_List>
    <Network>
      <Pathway_ID>ko04610</Pathway_ID>
      <Pathway_Title>Complement and coagulation cascades</Pathway_Title>
      <Pathway_Class>Organismal Systems</Pathway_Class>
      <Pathway_Subclass>Immune system</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko05164</Pathway_ID>
      <Pathway_Title>Influenza A</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Infectious diseases</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko05150</Pathway_ID>
      <Pathway_Title>Staphylococcus aureus infection</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Infectious diseases</Pathway_Subclass>
    </Network>
  </Network_List>
  <Fold>
    <SCOP_Class>All beta proteins</SCOP_Class>
    <SCOP_URL>http://scop.mrc-lmb.cam.ac.uk/scop/data/scop.b.c.ia.b.c.fg.html</SCOP_URL>
    <CATH_Class>Mainly beta</CATH_Class>
    <CATH_URL>http://www.cathdb.info/pdb/1ddj</CATH_URL>
  </Fold>
  <Enzyme_Nomenclature_List>
    <Enzyme_Nomenclature>
      <Enzyme_DB_ID>3.4.21.7</Enzyme_DB_ID>
      <Enzyme_DB_URL>http://www.chem.qmul.ac.uk/iubmb/enzyme/EC3/4/21/7.html</Enzyme_DB_URL>
    </Enzyme_Nomenclature>
  </Enzyme_Nomenclature_List>
  <Modulator_List>
    <Modulator>
      <ASD_ID>ASD00910001</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD02320001</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD02320002</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD02320003</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD02320004</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD02320005</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD02320006</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD02320007</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD02320008</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD02320009</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD02320010</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD02320011</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD02320012</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD02320013</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD02320014</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD02320015</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD02320016</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD02320017</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD02320018</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD02320019</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD02320020</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD02320021</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD02320022</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD02320023</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD02320024</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD02320025</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD02320026</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD02320027</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD02320028</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD02320029</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD02320030</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD02320031</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD02320032</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD02320033</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD02320034</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD02320035</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD02320036</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD02320037</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD02320038</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD02320039</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD02320040</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD02320041</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD02320042</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD02320043</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD02320044</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD02320045</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD02320046</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD02320047</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD02320048</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD02320049</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD02320050</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD02320051</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD02320052</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD02320053</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD02320054</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD02320055</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD02320056</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD02320057</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD02320058</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
  </Modulator_List>
  <Create_Date>2012-05-31</Create_Date>
</Organism_Record>